We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lentigen and ZGene Enter License Agreement for Selected ZGene Intellectual Property
News

Lentigen and ZGene Enter License Agreement for Selected ZGene Intellectual Property

Lentigen and ZGene Enter License Agreement for Selected ZGene Intellectual Property
News

Lentigen and ZGene Enter License Agreement for Selected ZGene Intellectual Property

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lentigen and ZGene Enter License Agreement for Selected ZGene Intellectual Property"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lentigen Corporation and ZGene A/S have announced that they have entered into an exclusive license agreement whereby Lentigen will obtain an exclusive license to certain specified proprietary ZGene multisubstrate kinase genes for certain indications.

These genes will allow Lentigen to create lentiviral vectors with increased safety by providing the capability to eliminate genetically modified cells from the body, if required.

Lentigen will be able to provide this safety feature to clients who purchase its custom lentiviral vectors.

ZGene will receive an upfront payment and additional milestone payments based on development and commercialization, as well as royalty payments on resulting products.

"This license agreement represents another important step in Lentigen's development," remarked Dr. Boro Dropulic, Founder and CEO of Lentigen.

"We believe that these genes will provide lentiviral vector technology with additional safety features not present in retroviral and lentiviral vectors currently under evaluation in human clinical trials."

"Lentigen aims to increase the safety of Lentiviral vector technology by the acquisition of technologies and by its own internal research and development efforts."

Zoran Gojkovic, CEO of ZGene, said, "This agreement is another commercial validation of our technology."

"Since the founding of the company, we have been purposefully and successfully expanding our gene portfolio to ensure that this technology remains at the forefront of drug activation."

"I am excited that Lentigen will combine our genes with lentiviral delivery and hope that this work will pave the way for better and safer treatments."

Advertisement